Markers of endothelial dysfunction and arterial stiffness in patients with early‐stage autosomal dominant polycystic kidney disease: A meta‐analysis-Reference-Cited by-同舟云学术

Markers of endothelial dysfunction and arterial stiffness in patients with early‐stage autosomal dominant polycystic kidney disease: A meta‐analysis

Published:2020-10-13 Issue:4 Volume:75 Page:
ISSN:1368-5031
Container-title:International Journal of Clinical Practice
language:en
Short-container-title:Int J Clin Pract

Author:

Bellos Ioannis¹^ORCID,Kontzoglou Konstantinos¹,Perrea Despina N.¹

Affiliation:

1. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas Athens University Medical SchoolNational and Kapodistrian University of Athens Athens Greece

Publisher

Hindawi Limited

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijcp.13721

Reference64 articles.

1. Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease

2. Autosomal dominant polycystic kidney disease

3. Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases

4. Metabolism and mitochondria in polycystic kidney disease research and therapy

5. Autosomal Dominant Polycystic Kidney Disease

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Cardiovascular Disease in Autosomal Dominant Polycystic Kidney Disease;Applied Sciences;2023-06-15

2. Microvascular perfusion, perfused boundary region and glycocalyx shedding in patients with autosomal dominant polycystic kidney disease: results from the GlycoScore III study;Clinical Kidney Journal;2022-10-19

3. Rapidly Progressing to ESRD in an Individual with Coexisting ADPKD and Masked Klinefelter and Gitelman Syndromes;Genes;2022-02-23

4. miRNA-16 as a predictive factor for intracranial aneurysms in autosomal dominant polycystic kidney disease;Neurologia i Neurochirurgia Polska;2021-06-30

5. Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease;Therapeutics and Clinical Risk Management;2021-06